EZH2 and breast carcinoma: To initially examine the impact of combined inhibition of HOTAIR and EZH2, we treated ovarian and breast cancer cells with HOTAIR siRNA plus EZH2 catalytic activity inhibitor (GSK126), observing increased chemotherapy sensitivity and reduced cell survival (Fig. 1A).